TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xenon ( (XENE) ) has provided an update.
Xenon Pharmaceuticals announced its participation in the American Epilepsy Society Annual Meeting (AES 2025) with multiple presentations, including new long-term data from the X-TOLE open-label extension study of azetukalner for focal onset seizures, and insights into the impact of depression on epilepsy patients. The presentations aim to inform future clinical practices and highlight the company’s ongoing research in Dravet syndrome, potentially impacting treatment approaches and stakeholder interests in the epilepsy treatment landscape.
The most recent analyst rating on (XENE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. The company operates within the biopharmaceutical industry, focusing on neurological disorders, with a particular emphasis on epilepsy and related conditions.
Average Trading Volume: 756,583
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.25B
For a thorough assessment of XENE stock, go to TipRanks’ Stock Analysis page.